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Objective. To determine whether treatment with
an antiresorptive drug in combination with an anti-
inflammatory drug reduces periarticular bone and soft
tissue adaptations associated with the progression of
posttraumatic secondary osteoarthritis (OA).
Methods. We used in vivo microfocal computed
tomography (micro-CT) to map bony adaptations and in
vivo micro–magnetic resonance imaging (micro-MRI) to
examine joint inflammation in a rat model of surgically
induced OA secondary to knee triad injury. We exam-
ined the arthroprotective effects of the bisphosphonates
alendronate and risedronate and the nonsteroidal anti-
inflammatory drug (NSAID) meloxicam.
Results. Micro-CT revealed reduced levels of peri-
articular trabecular bone loss in animals with knee
triad injury treated with the bisphosphonate drugs
alendronate or risedronate, or the NSAID meloxicam,
compared with untreated animals. Alendronate treat-
ment reduced bony osteophyte development. While
risedronate as a monotherapy did not positively impact
osteophytogenesis, combination therapy with rised-
ronate and meloxicam reduced osteophyte severity
somewhat. Micro-MRI revealed an increased, diffuse
water signal in the epiphyses of untreated rats with knee
triad injury 8 weeks after surgery, suggestive of a bone
marrow lesion–like stimulus. In contrast, meloxicam-
treated rats showed a significant reduction in fluid
signal compared with both bisphosphonate-treated
groups 8 weeks after surgery. Histologic analysis qual-
itatively confirmed the chondroprotective effect of both
bisphosphonate treatments, showing fewer degradative
changes compared with untreated rats with knee triad
injury.
Conclusion. Our findings indicate that select
combinations of bisphosphonate and NSAID drug ther-
apy in the early stages of secondary OA preserve
trabecular bone mass and reduce the impact of osteo-
phytic bony adaptations and bone marrow lesion–like
stimulus. Bisphosphonate and NSAID therapy may be
an effective disease-modifying drug regimen if adminis-
tered early after the initial injury.
Traumatic injury to the knee joint (such as liga-
ment disruption or meniscal damage) predisposes to
secondary osteoarthritis (OA), a debilitating disease of
the joints characterized by the focal deterioration and
eventual full-thickness loss of articular cartilage and by
periarticular bone and soft tissue adaptations. Radio-
graphic evidence of OA includes narrowing of the joint
space after cartilage damage, with accompanying
changes in periarticular trabecular bone and/or osteo-
phyte formation at the joint margins and ligament
entheses. Accordingly, periarticular bony adaptations
may be useful as progressive prognostic indicators (and
as potential therapeutic drug targets) of OA, particularly
during the early stages of OA pathogenesis (1,2).
Osteophytes arise on bone at the synovial joint
margins, from activated cells of the periosteum, initially
appearing as cartilaginous growths that later calcify via
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endochondral ossification (3). Mediators of inflamma-
tion secreted by the synovium, such as interleukin-1,
tumor necrosis factor , and transforming growth factor
, are believed to be involved in osteophytogenesis (4,5).
Osteophytes are known to cause joint stiffness by limit-
ing the movement of the joint (6) and leading to fixed
bony deformity, and thus are permanent bony changes
that increase the severity of OA, and are strong predic-
tors of OA-related pain (7). Therefore, the reduction of
osteophyte incidence using drugs known to influence
bone mass (such as the bisphosphonates), and/or drugs
capable of blocking the potential costimulation of osteo-
phytogenesis by mediators of inflammation (such as
nonsteroidal antiinflammatory drugs [NSAIDs]), re-
mains a viable disease-modifying goal of OA therapy.
Our study focused on the reported ability of
alendronate to block osteophytosis (8), a process that
the closely related bisphosphonate drug risedronate has
not been shown to influence (9). The aim of our study
was to determine whether the use of bisphosphonate
drugs at an early stage of OA pathogenesis reduced
periarticular bony adaptations (such as osteophyte se-
verity) and/or cartilage degradation in OA. We also
examined whether the addition of an NSAID to that
regimen would further reduce osteophytic OA joint
adaptations. The NSAID meloxicam is a selective cyclo-
oxygenase 2 (COX-2) inhibitor (10), with known anti-
inflammatory and antiangiogenic effects (11–13).
NSAIDs are prescribed primarily for the management of
OA pain (14,15); however, they have also been found to
have positive effects on cartilage health in OA by
increasing proteoglycan and hyaluronan synthesis (16).
Thus, we hypothesized that the addition of an NSAID to
the bisphosphonate drug regimen may further mediate
the reduction of the inflammatory stimulus and prove
beneficial in preventing or slowing osteophytes and
cartilage degradation. Our study further tested the util-
ity of 2 different multimodal noninvasive imaging tech-
nologies (high-resolution in vivo microfocal computed
tomography [micro-CT] and in vivo micro–magnetic
resonance imaging [micro-MRI]), with subsequent his-
tologic validation, to assess mineralized and soft tissue
adaptations indicative of OA.
MATERIALS AND METHODS
Surgically induced OA in an animal model. Fifty-eight
6-week-old (275-gm) female Sprague-Dawley rats were ob-
tained from the University of Alberta Biosciences Animal
Services. The protocol pertaining to all procedures and aspects
of the study was approved by the University of Alberta animal
care and ethics committee. OA pathogenesis was surgically
induced in 46 of the rats, using the surgical knee triad injury
model of knee OA, performed as previously described (17).
Only the right knee (stifle) joint was operated upon. All rats
received a single dose of an opioid analgesic (buprenorphine)
on the first day after surgery only, since rats resumed active
caged activity with no indication of morbidity. Briefly, a medial
capsulotomy was performed, and knee triad injury was induced
in rats by transection of the medial collateral ligament (MCL)
at its midpoint, removal of the medial meniscus after severing
the anchoring horns, and midsubstance transection of the
anterior cruciate ligament (ACL). Eight rats underwent sham
surgery in which the joint was surgically exposed, and the
MCL, medial meniscus, and ACL were manipulated but left
intact. Sterile saline was used to flush joint surfaces, and the
capsule and skin were sutured using 5-0 Vicryl. Surgery was
performed using 1.5% isoflurane/L oxygen inhalation anesthe-
sia. All animals were killed 8 weeks after surgery, and the
femur and tibia were then isolated and fixed in neutral
buffered formalin (pH 7.0).
Experimental design. Our investigation was conducted
in 2 stages, using age-matched cohorts of rats. The initial phase
focused on the comparison of risedronate and alendronate as
disease-modifying OA drugs (DMOADs). Six-week-old
(275-gm) female Sprague-Dawley rats were randomly allo-
cated into the following 4 groups: rats with knee triad injury
treated with alendronate (n  8), rats with knee triad injury
treated with risedronate (n  8), untreated rats with knee triad
injury (n  6), and untreated sham-operated rats (n  8).
The second stage focused on the assessment of the
potential of meloxicam as a DMOAD, either as a monotherapy
or in combination with a bisphosphonate drug. For all in vivo
micro-MRI measurements, a random subset of 4 rats per
group was imaged due to the expense of operating the 9.4T
system. For this stage of the study, a second cohort of 6-week
old (275-gm) female Sprague-Dawley rats was obtained from
the same supplier (University of Alberta Biosciences Animal
Services) and randomly allocated into the following 5 groups:
rats with knee triad injury treated with meloxicam (n  8), rats
with knee triad injury treated with meloxicam and risedronate
(n  8), rats with knee triad injury treated with risedronate
(n  4), untreated rats with knee triad injury (n  4), and
untreated uninjured rats (n  4).
Drug dosage. All treatments lasted for 8 weeks, from
the day after surgery until the experimental end point (when
rats were killed). Eight rats with knee triad injury received 0.12
mg/kg body mass of alendronate twice weekly by subcutaneous
injection. This concentration corresponded to the “high” dose
established in previous studies using a rat model of OA (8).
Risedronate 0.06 mg/kg body mass was administered twice
weekly by subcutaneous injection to 12 rats with knee triad
injury and to 8 rats with knee triad injury that were also treated
with meloxicam. This corresponded to an effective dose for
preventing bone loss that was established in previous studies
(9). The dosage of risedronate was half that of alendronate,
due to the increased potency of risedronate, and corresponded
with the relative dosing currently used in bisphosphonate
treatment of osteoporosis in humans.
Meloxicam was administered to rats by daily oral
gavage at a dose of 3 mg/kg as previously described (18), using
an 18-gauge, 2-inch curved animal feeding needle (Harvard
Apparatus). The meloxicam was suspended in a 60:40 solution
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of propylene glycol and distilled water at a concentration of 1
mg/ml. For meloxicam administration, food was withheld from
rats for 2 hours before and after drug dosing. Vehicle was
injected subcutaneously twice weekly in untreated rats with
knee triad injury and sham-operated rats. For combination
therapy, the bisphosphonate was injected first subcutaneously,
and then food was withheld from rats for 2 hours before and
after meloxicam dosing as described above. To confirm the
plasma levels of meloxicam, blood samples were obtained from
rats at Tmax (time to maximum plasma concentration) after an
oral dose of meloxicam and sampled after in vivo micro-CT
imaging while rats were under anesthesia. Plasma levels of
meloxicam were determined using reverse-phase high-
performance liquid chromatography (HPLC) as previously
described (18). HPLC conditions consisted of a buffered
mobile phase of 50 mM sodium phosphate, methanol, and
acetonitrile in a 5:4:1 ratio (volume/volume). Flow rate was 1.0
ml/minute with a C-18 solid-phase column and an ultraviolet
detection wavelength of 364 nm.
In vivo micro-CT. In vivo micro-CT was performed at
3 time points: 1 day prior to surgery, 4 weeks after surgery, and
when rats were killed 8 weeks after surgery. Isoflurane (Halo-
carbon) was used as the anesthetic for the duration of the
procedure (35 minutes). Rats were placed supine in the bed
of a Skyscan 1076 in vivo X-ray microtomograph. The right
hind limb was extended and secured to the gantry bed using
masking tape to limit movement. Radiographs encompassed
the entire stifle joint in a single field of view. Two-dimensional
(2-D) projections were obtained using an x-ray source setting
of 70 kV and 139 A, with beam filtration through a 1.0-mm
aluminum filter. Data were collected every 0.5° rotation step
through 180°. The scanning width was 35 mm, and the height
was 17 mm. Reconstruction was performed using a modified
Feldkamp back-projection algorithm with a cross-section to
image of 0.0000–0.0602. The resulting slices were composed of
isotropic voxels with a resolution of 17.46 m3. Bone mor-
phometry was determined using Skyscan CT-Analyser Soft-
ware. A 1.53-mm3 sphere was centered in the epiphyseal
trabecular bone of the medial condyle of the distal femur and
sampled to assess the bone volume percentage. The sphere
defined a volume of interest that included only trabecular
bone, and a single observer (MDJ) performed the measure-
ments to improve consistency in sphere placement. Micro-CT
images were binarized with a grayscale threshold of 60/255.
To assess osteophyte severity, 2 independent observers
(MDJ and GL) who were blinded with regard to treatment
group visually scored 3-D micro-CT models of the femur and
tibia from each rat. Osteophyte severity was graded on a
4-point scale, where 0  no observed osteophytes, 1 
localized and less severe osteophytosis, 2  widespread but
moderately severe osteophytosis, and 3  widespread and very
severe osteophytosis. An average of the individual observer
scores was calculated for each rat, and the average osteophyte
score for each treatment group was then determined.
In vivo micro-MRI. We used a Magnex Scientific in
vivo 9.4T high-field micro-MRI to scan the same stifle joint in
each rat. Eight weeks after surgery, rats were scanned in vivo
under isoflurane anesthesia. The rat was placed supine in the
MRI bed, and the right hind limb was extended and secured as
described above. Using a flat surface-acquisition coil, we
acquired images with anisotropic voxels with a resolution of
137  137  500 m. The MRI was operated in a fat-
suppressed, spin-echo, T2-weighted scan mode specifically to
visualize potential bone marrow lesion–like/edema-like phe-
nomena in the tissue, as previously described (19,20). Each
scan was 15 minutes in duration. Sagittal slices of the medial
femoral condyle were selected from each data set, and the
epiphyseal water signal was quantified using ImageJ analysis
software (NIH Image, National Institutes of Health, Bethesda,
MD; online at: http://rsbweb.nih.gov/ij/). The mean visual pixel
intensity within a 1.8-mm diameter circular region of interest,
anatomically landmarked by the metaphyseal growth plate and
the cortical bone margins, was assessed by a single observer
(MDJ).
Histologic assessments. After the rats were killed, both
the tibia and the femur were dissected from each animal, and
the bones were fixed in neutral buffered formalin. After 2
weeks in fixative (with multiple changes), the samples were
placed in formic acid–formaldehyde decalcification solution
(Cal-EX II; Fisher Scientific) for a further 2 weeks. Decalcified
samples were paraffin embedded and sectioned at 6 m, and
the mounted slides were stained with either toluidine blue or








Sham-operated rats (n  8) 46.45  7.5 0.10  0.01 0.25  0.00§
Untreated rats with knee triad injury (n  6) 37.41  8.4 2.00  0.16¶ 5.01  0.70
Alendronate-treated rats with knee triad injury (n  8) 49.51  9.2§ 1.38  0.38¶ 3.09  0.36
Risedronate-treated rats with knee triad injury (n  8) 42.06  4.4 1.94  0.29¶ 3.31  0.31
Meloxicam-treated rats with knee triad injury (n  8) 64.35  4.4# 1.88  0.26¶ 4.83  0.75
Combination-treated rats with knee triad injury (n  8) 56.17  7.1§ 1.69  0.27¶ 3.00  0.63
Untreated uninjured rats (n  8) 55.52  4.2§ NA NA
* Values are the mean  SEM. Rats with knee triad injury had surgically induced osteoarthritis. Rats in the combination treatment group were
treated with a combination of risedronate and meloxicam. NA  not applicable.
† Higher scores (maximum 3.0) indicate greater osteophyte severity.
‡ Higher scores (maximum 13.0) indicate greater cartilage damage.
§ P  0.05 versus untreated rats with knee triad injury.
¶ P  0.05 versus sham-operated rats.
# P  0.05 versus combination-treated rats with knee triad injury, risedronate-treated rats with knee triad injury, untreated rats with knee triad
injury, and untreated uninjured rats.
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Safranin O to assess cartilage health using a modified Mankin
scoring system (21). Slides were assessed in a randomized
manner by 2 independent observers (MDJ and GL) who were
blinded with regard to study group, and the average of the 2
scores was used for analysis.
Statistical analysis. Results are presented as the
mean  SEM. Statistical analyses were conducted using the
SPSS statistics software package (version 13.0; SPSS). The
nonparametric Mann-Whitney test was used to compare qual-
itative histology and osteophyte scores. For the quantitative
measures of bone volume, unpaired t-tests were used to
compare groups. P values less than 0.05 were considered
significant.
RESULTS
Assays of plasma meloxicam concentrations.
Plasma concentrations of meloxicam in the rats were
analyzed using an HPLC assay. Meloxicam eluted the
column at or near 3.65 minutes and piroxicam, the
internal standard, at or near 2.70 minutes, with sufficient
resolution between the peaks. Our standard curve cor-
relation R2 value was equal to 0.999, and the plasma
samples, which were obtained at Tmax as described above
from all rats treated with meloxicam (whether alone or
in combination with risedronate), had a mean  SEM
meloxicam concentration of 24.13  7.30 g/ml. Rats
that received meloxicam alone had a mean plasma
concentration of 33.43 g/ml, and rats that received
combination therapy (meloxicam and risedronate) had a
mean plasma concentration of 20.41 g/ml. The differ-
ence in plasma meloxicam concentration between rats
treated with meloxicam alone and those treated with a
combination of meloxicam and risedronate was not
statistically significant.
Results of in vivo micro-CT analysis. The early
effects of OA pathogenesis on periarticular bone mass
were assessed by measuring the trabecular bone volume
percentage in a spherical region of interest within the rat
medial femoral condyle (Table 1), using micro-CT data
sets. Both bisphosphonates preserved trabecular bony
tissue over the 8-week period of developing OA. Rela-
tive to the untreated animals with knee triad injury,
trabecular bone volume was significantly higher in
alendronate-treated animals (12.1%), and slightly in-
creased in risedronate-treated animals (4.65%).
Using micro-CT–based bone volume measure-
ments, we did not find any significant thickening or
sclerosis of the subchondral bone plate in this rat model
of OA up to 8 weeks after knee triad injury (data not
shown). However, micro-CT measurements revealed a
significantly increased zone of provisional calcification
at the primary spongiosum of the growth plates in all
animals treated with any bisphosphonate drug, either as
a monotherapy or in combination with meloxicam (data
not shown). These observations clearly indicate altered
Figure 1. Microfocal computed tomography of osteophyte develop-
ment in the same knee of an untreated rat 1 day before knee triad
injury surgery (0 weeks) and 8 weeks after surgery. Arrows indicate
areas of osteophyte development. A, Transverse slice through the
distal femoral epiphysis. B and C, Three-dimensional renderings of the
medial aspect (B) and anterior aspect (C), illustrating severe osteo-
phyte development.
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bone remodeling due to the effects of the potent
bisphosphonate drugs. However, the effects of bisphos-
phonates on the nonfused long bone growth plates in the
juvenile, growing rats used in this study were not ad-
dressed.
Osteophyte growth and severity were assessed
qualitatively using 3-D renderings of micro-CT of rat
distal femoral bone obtained 8 weeks after surgery
(Figure 1 and Table 1). All groups with knee triad injury
exhibited osteophytes, with untreated rats with knee
triad injury exhibiting severe osteophytosis 8 weeks after
surgery (mean score 2.0 [maximum 3.0]). Although
osteophyte severity scores for animals treated with alen-
dronate were lower (mean score 1.38 [maximum 3.0]),
they were not significantly different from the scores in
untreated mice with knee triad injury.
In the second part of our study, temporal evalu-
ations of changes in trabecular bone volume (for all
treatment groups) were conducted using in vivo
micro-CT in the same rats at time 0 (1 day before
surgery) and 4 weeks and 8 weeks after knee triad injury
surgery. All randomly assigned groups of rats had an
equal trabecular bone volume percentage in the distal
femoral epiphysis at time 0. Furthermore, we noted that
the trabecular bone volume increased in all groups (both
injured and normal controls) from baseline to week 4
and from week 4 to week 8, likely representing the
Figure 2. End-stage knee osteoarthritis in the same rat knee viewed
by microfocal magnetic resonance imaging (micro-MRI) and microfo-
cal computed tomography (micro-CT). T2-weighted, fat-suppressed
MRIs were obtained using a 9.4T system, and micro-CT images were
obtained at a resolution of 18 m. The same subchondral bone cyst
(red arrows) was observed using both imaging techniques. MRI
further revealed an epiphyseal bone marrow lesion–like signal (encir-
cled areas) and delineated the thin metaphyseal growth plate (white
arrows), while micro-CT showed the associated bone microarchitec-
ture in those anatomic regions at high resolution.
Figure 3. T2-weighted, fat-suppressed microfocal magnetic resonance
images of osteoarthritic rat knees 8 weeks after knee triad injury surgery.
Images were obtained in the sagittal plane, and the slice transecting the
medial condyle of the femur is shown. Images were obtained of A, a
sham-operated control, B, an untreated rat with knee triad injury, C, a rat
with knee triad injury treated with risedronate, D, a rat with knee triad
injury treated with alendronate, E, a rat with knee triad injury treated with
meloxicam, and F, a rat with knee triad injury treated with a combination
of risedronate and meloxicam. Minimal to no water signal was detected in
the sham-operated control rats. Untreated rats with knee triad injury,
risedronate-treated rats with knee triad injury, and alendronate-treated
rats with knee triad injury showed strong water signals resembling bone
marrow lesions in the epiphyseal bone marrow space. Meloxicam as a
monotherapy, or in combination with risedronate, reduced the bone
marrow lesion–like signal intensity.
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natural skeletal growth of those rats (data not shown).
When we examined the effects of meloxicam, we found
an unexpected and significantly increased trabecular
bone volume percentage 8 weeks after knee triad injury
surgery in the meloxicam-treated rats compared with all
other treatment groups (except for the alendronate-
treated group) at the same time point (P  0.05) (Table
1). The group treated with a combination of risedronate
and meloxicam also exhibited significantly preserved
trabecular bone mass compared with untreated rats with
knee triad injury (P  0.05). With regard to osteophyto-
sis, the group treated with a combination of risedronate
and meloxicam showed a trend toward reduced osteo-
phytosis, but the osteophyte severity score was not
significantly different from that in untreated rats with
knee triad injury.
Results of in vivo micro-MRI analysis. Using
micro-MRI, we visualized the same region in the rat
knee joint that was assessed by micro-CT, and we
observed increased T2 signal inside the epiphyseal sub-
chondral bone marrow of rats with knee triad injury 8
weeks after surgery (Figure 2). We used the endosteal
bone envelope (in the 2-D MRI slices) as anatomic
landmarks and constraints for measurements of the
epiphyseal bone compartment. Fat-suppressed, T2-
weighted micro-MRIs of normal uninjured rats exhib-
ited a discrete, thin T2 signal corresponding to the
metaphyseal growth plate. In marked contrast, increased
T2 signal was observed at the same location in the
epiphyseal bone of untreated rats with knee triad injury,
suggestive of a bone marrow lesion–like/edema-like in-
flammatory abnormality (Figure 3). Significantly in-
creased T2 signal intensity was measured in rats with
knee triad injury treated with risedronate and rats with
knee triad injury treated with alendronate compared
with sham-operated normal controls (P  0.05) (Figure
4). Conversely, the rats with knee triad injury that were
treated with the antiinflammatory drug meloxicam, ei-
ther as a monotherapy or in combination with risedr-
onate, had decreased T2 signal compared with rats with
knee triad injury treated with risedronate and untreated
rats with knee triad injury 8 weeks after surgery. The T2
signal in rats treated with meloxicam was not statistically
different from that in sham-operated normal controls.
Results of histologic analysis. All histologic ana-
lysis was performed after rats were killed at the 8-week
time point. Each sample was scored using a modified
Mankin scoring scheme (Table 1). Eight weeks after
surgery, untreated rats with knee triad injury had devel-
oped clear indications of cartilage and bone changes
indicative of posttraumatic OA. An average modified
Mankin score of 5.0 was observed in the untreated group
with knee triad injury (P  0.05 versus untreated
sham-operated rats). Both animals with knee triad injury
treated with risedronate and animals with knee triad
injury treated with alendronate showed improved carti-
lage health compared with the untreated rats with knee
triad injury (average score 3.3 for risedronate-treated
animals and 3.1 for alendronate-treated animals), al-
though these differences were not statistically signifi-
Figure 4. Pixel intensity of a sampled region of epiphyseal trabecular bone, as
centered on the metaphyseal growth plate, assessed 8 weeks after surgery to quantify
the presence of bone marrow lesions in sham-operated rats, untreated rats with knee
triad injury (KTI-untreated), rats with knee triad injury treated with risedronate
(KTI-Ris), rats with knee triad injury treated with meloxicam (KTI-meloxicam), rats
with knee triad injury treated with a combination of risedronate and meloxicam
(KTI-Combo), and rats with knee triad injury treated with alendronate (KTI-Alen).
Bars show the mean and SEM. †  P  0.05 versus sham-operated rats.
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cant. Similarly, rats with knee triad injury treated with a
combination of meloxicam and risedronate demon-
strated a decrease in degradative OA cartilage changes
relative to the untreated rats with knee triad injury
(average score 3.0). However, meloxicam as a mono-
therapy did not improve degradative OA cartilage
changes in rats with knee triad injury (average score 4.8)
compared with untreated rats with knee triad injury.
Histologic examination did not reveal any partic-
ular cellular event to which the bone marrow lesion–like
phenomenon (seen on micro-MRI in those same bone
samples) could be attributed, other than what appeared
to be the increased vasodilation of vascular capillaries,
which resulted in the pooling of erythrocytes (and likely
fluid) in the marrow space. The erythrocyte pooling was
difficult to discern under routine hematoxylin and eosin
staining (Figures 5A and B) but became powerfully
apparent using Safranin O to stain nuclei red, with a fast
green counterstain that rendered the erythrocytes green-
blue to purple in color (Figures 5C–F). In the
meloxicam-treated samples, the vasodilation appeared
reduced, with fewer pools of erythrocytes. We did not
observe any evidence of leukocytic infiltration over the
abundant marrow stromal cells in any of the groups.
DISCUSSION
Despite the prevalence of OA in the aging pop-
ulation, there are no currently approved DMOADs (22).
The analgesic acetaminophen is the first-line therapy
indicated for OA treatment and is used for pain man-
agement, with no known disease-modifying benefits.
Several bisphosphonate drugs have previously been
shown to have disease-modifying treatment outcomes in
OA in animal models (23–25) and humans (26–28).
However, those studies had contradictory results regard-
ing the disease-modifying efficacy of bisphosphonate
drugs, particularly since most studies in humans involved
patients with end-stage OA, rather than individuals at an
earlier stage of OA pathogenesis.
In this study, we evaluated the disease-modifying
effects of the bisphosphonate drugs risedronate and
alendronate and the NSAID meloxicam on the progres-
sion of posttraumatic OA in an established rat model
(25,29,30). We found that alendronate significantly, and
risedronate to some degree, reduced trabecular bone
volume loss in the medial femoral compartment com-
pared with untreated rats early after a knee triad injury.
These findings were consistent with those of previous
studies examining posttraumatic OA in several other
animal models (9,31) and were also supported by the
results of investigations of risedronate in later-stage
human OA (26).
With respect to osteophytosis, risedronate did
not reduce or retard bony osteophyte development in
rats with knee triad injury, which was consistent with
previous results in a rabbit model of OA (9). In contrast,
alendronate showed a trend toward reducing the num-
ber and severity of osteophytes in the rat knee triad
injury model, although the results were not statistically
significant compared with the untreated rats with knee
triad injury. Our findings are consistent with those of an
Figure 5. Histologic analysis of trabecular bone from the distal fem-
oral epiphyses of rats that exhibited a bone marrow lesion–like
presentation on microfocal magnetic resonance imaging. A and B,
Hematoxylin and eosin (H&E) staining of sections from rats with knee
triad injury treated with alendronate (A) and rats with knee triad injury
treated with risedronate (B) (magnification  20). C–E, Safranin O
staining of nuclei (red) with fast green counterstaining of erythrocytes
(green-blue to purple) of sections from rats with knee triad injury
treated with risedronate (original magnification  20 in C;  40 in D
and E). F, Safranin O staining of nuclei (red) with fast green
counterstaining of erythrocytes (green-blue to purple) of sections from
rats with knee triad injury treated with meloxicam (magnification 
20). There was increased vasodilation of vascular capillaries (arrows),
resulting in the pooling of erythrocytes (and likely fluid) in the marrow
space. Erythrocyte pooling was difficult to discern under routine H&E
staining (A and B), but became powerfully apparent with Safranin O
and fast green counterstaining (C–F). In the meloxicam-treated sam-
ples, the vasodilation appeared reduced, with fewer pools of erythro-
cytes seen.
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earlier study (8) and suggest that alendronate inhibits
osteophytogenesis by an alternative mechanism. This
mechanism by which alendronate exerts its antiosteo-
phytic activity remains to be determined and is a poten-
tial direction for further research.
In the second part of our study, we found that the
NSAID meloxicam not only preserved bone volume
after a knee triad injury, but also, surprisingly, led to
increased bone volume compared with all other treat-
ment groups. As a selective inhibitor of the inducible
mediator of inflammation COX-2, meloxicam was pre-
viously shown to negatively impact bone healing (32),
possibly since COX-2 regulates genes that are critical for
osteoblast differentiation (33). This reduced periosteal
osteoblastogenesis would therefore likely also reduce
subsequent endochondral bone formation. However, the
increased epiphyseal trabecular bone volume observed
in our study is supported by the observation that disrup-
tion of COX-2 gene expression by meloxicam also
results in reduced RANKL and osteoprotegerin expres-
sion in osteoblasts (34). Thus, a reduction in RANKL
levels may have contributed to the maintenance of bone
mass in the group of rats with knee triad injury treated
with meloxicam. On the other hand, the reduced remod-
eling observed in all bisphosphonate-treated groups can
be attributed to the effects of the potent bisphosphonate
drugs. In that scenario, the combination therapy likely
did not increase the amount of trabecular bone since
bone formation was suppressed by the action of the
potent N-containing bisphosphonate drug; this is a well-
known consequence of the use of bisphosphonate drugs
(35).
It is also important to note that in the present
study bone volume percentages appeared to have in-
creased in all groups between the first and second stage
of the study (data not shown). These changes could
represent differences in the ages of the rat test popula-
tions in the first and second parts of the study, since they
were supplied based on body mass. Nonetheless, relative
to the untreated rats with knee triad injury and un-
treated uninjured rats in the second part of the study, the
rats with knee triad injury treated with meloxicam had a
significantly higher bone volume percentage. Interest-
ingly, rats treated with both risedronate and meloxicam
did not display any synergistic effects in increased bone
volume, but had less bone volume than that observed in
rats treated with meloxicam alone. The addition of
risedronate may have reduced metaphyseal osteoblastic
activity and resulted in reduced bone volume compared
with rats treated with meloxicam alone.
Beyond the changes observable on radiography,
OA may present pathophysiology that can be detected
using physiologic imaging modalities such as MRI. One
such phenomenon is a bone marrow lesion (historically
termed bone marrow edema), which presents as a high-
intensity, diffuse fluid signal within the epiphyses of the
femur and tibia of many patients with knee OA (19,20).
A bone marrow lesion is identified by increased signal
on fat-suppressed, T2-weighted scans, with lower signal
contrast to background in T1-weighted scans of the same
subchondral bone marrow region. The histologic char-
acteristics of bone marrow lesions in OA remain a
subject of controversy. Necrotic bone marrow, bone
marrow fibrosis, and occasionally bone marrow edema
have been associated with bone marrow lesions in OA
(36), and bone marrow lesions are frequently observed
in association with the cartilage degradation seen in OA
(37). Patients who exhibit bone marrow lesions are more
likely to develop severe OA over the subsequent 15–30
months (38), and thus, the early detection of bone
marrow lesions with cartilage deterioration may improve
the management and treatment of OA.
A major finding of our study was the diffuse,
bone marrow lesion–like fluid phase we detected on
fat-suppressed, spin-echo, T2-weighted micro-MRIs of
the distal femoral epiphyseal marrow space, 8 weeks
after injury, in untreated rats with knee triad injury. In
stark contrast, a very thin and discrete fluid signal was
evidenced in the epiphyses of normal control rats with
no surgical injury, suggesting a quiescent basal level of
fluid content. In rats with knee triad injury treated with
alendronate and rats with knee triad injury treated with
risedronate, the diffuse bone marrow lesion–like fluid
phase remained 8 weeks after knee triad injury surgery.
Conversely, the rats with knee triad injury treated with
meloxicam showed a reduced bone marrow lesion–like
signal, suggestive of a treatment-based antiinflammatory
outcome. The bone marrow lesion–like phenomenon
identified using micro-MRI may have a potential appli-
cation as a measure of OA disease progression and drug
efficacy in this posttraumatic rat OA model, and war-
rants further detailed investigation.
Histologic assessment of the knee joint using a
modified Mankin scoring system revealed that the
bisphosphonates alendronate and risedronate tended to
reduce the progression of OA and maintain cartilage
health in this short-term study, although the results were
not statistically significant compared with findings in
untreated controls with knee triad injury. Those modest
chondroprotective effects were consistent with the pre-
viously demonstrated positive effects of alendronate
therapy in OA (8), and were also supported by the
results of investigations of risedronate in later-stage
human OA (27,28,39).
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In conclusion, our data suggest that bisphospho-
nates and meloxicam potentially reduce the progression
of OA following joint trauma in the rat knee triad injury
model and could have additional clinical applications
regarding the management of secondary OA. Alendro-
nate and meloxicam were effective in maintaining and
increasing bone volume, respectively, while alendronate
also displayed some positive effects in inhibiting osteo-
phytosis. Meloxicam alone, or in combination with
risedronate, reduced the bone marrow fluid signal at the
site of knee triad injury when quantified and compared
with signal in sham-operated normal controls. Further
research is necessary to elaborate on the precise mech-
anisms by which bisphosphonates and meloxicam oper-
ate in inhibiting the periarticular bone– and fluid-based
changes associated with joint damage secondary to
trauma. The findings of our study may be applicable in
the pharmacologic management of disease following
joint damage, secondary to traumatic rupture of the
ACL and/or medial meniscus, as is often encountered in
sports injuries. In those situations, it may prove feasible
to conservatively manage and preserve periarticular
bone microarchitecture and retard osteophyte formation
by using bisphosphonates and NSAIDs as combination
therapy for a discrete therapeutic window immediately
after the injury and prior to subsequent surgical joint
reconstruction.
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